echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Imperial and Bayer use AI in the development of new drugs for heart disease

    Imperial and Bayer use AI in the development of new drugs for heart disease

    • Last Update: 2021-02-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    imperial and Bayer Pharmaceuticals are working together to explore how artificial intelligence (AI) can be used to accelerate the development of new drugs for heart disease.The partner plans to develop machine learning tools to analyze 3D heart imaging, as well as genetic information, as part of a new approach to drug discovery.2018 is the year when companies adopt artificial intelligence and machine learning, ushering in an era of faster, cheaper and more effective drug development.The new partnership will use data from biobank UK, a national health resource that contains a wealth of information on 500,000 people in the UK, to enable them to identify ways to treat heart disease that could provide new targets.Dr Declan O'Regan, from the MRC London Institute of Medical Sciences, said: "Artificial intelligence has the potential to change our understanding of heart disease and accelerate the discovery of new treatments. Our partnership with Bayer will use state-of-the-art computer vision algorithms and advanced statistical techniques to understand the relationship between genetic variation and heart movement using data collected by Biobank UK.“ This academic-industrial partnership is achieved through innovative interdisciplinary research that connects imaging, machine learning, and clinical pharmacology, and reflects the Empire's dedication to driving the practical application of artificial intelligence in medical research. However seven million people in the UK alone suffer from heart disease and circulatory diseases, of which cardiovascular disease causes a quarter of deaths. (Compiled by this web)
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.